ClinicalTrials.gg
CompletedNCT04776239ACESO-IHDUpdated Jun 16, 2026Results posted

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

A Phase 1/2 interventional study of 100 million Allogeneic Mesenchymal Human Stem Cells and Placebo in Diabetes Mellitus and Ischemic Heart Disease, sponsored by Joshua M Hare. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Joshua M Hare · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,023 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 388 under way, 12 of them phase 3. Diabetes Mellitus · United States.

Enrollment
1,906th of 2,502
26 · median 82
Started
2021
with 112 others
Phase 1/2
58 of 3,023
5 open now
Registered
2,475th of 3,023
by date

Among the 3,023 studies in Diabetes Mellitus with a site in United States, this one is the 1,906th largest by enrollment of the 2,502 interventional ones that give a count, is one of 113 that started in 2021, is one of 58 in phase 1/2, and was the 2,475th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

289 of the 3,023 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:

284 more — sign in →

All 289 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,023 studies in Diabetes Mellitus with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to test the hypothesis that allogeneic Mesenchymal Stem Cells (MSCs) promote systemic and coronary endothelial repair through rescue of bone marrow progenitors in type 2 diabetic patients with symptomatic IHD compared to placebo.

03

Conditions studied

  • Diabetes Mellitus
  • Ischemic Heart Disease

Keywords

  • Endothelial dysfunction
  • Diabetes
  • Stem cells
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be ≥ 18 years of age (males and females).
  2. Provide written .
  3. Have a diagnosis of symptomatic ischemic heart disease (IHD) and an indication for standard-of-care coronary angiography.
  4. Have Diabetes Mellitus (DM) type 2 documented by (HbA1C) > 7%, or on medical therapy for diabetes.

Exclusion criteria

Exclusion Criteria:

  1. Be younger than 18 years of age.
  2. Have history of prior myocardial Infarction and revascularization.
  3. Have a baseline (GFR) \<30 ml/min 1.73m2 estimated using the Modification of Diet for Renal Disease (MDRD) formula.
  4. Have poorly controlled blood glucose levels with > 8.5% in the previous 3 months.
  5. Have a history of proliferative retinopathy or severe neuropathy requiring medical treatment.
  6. Have an indication for standard-of-care surgical (including valve surgery, placement of left-ventricular assist device) or percutaneous intervention for the treatment of valvular heart disease (including valvuloplasty).
  7. Have known or to aspirin; both heparin and bivalirudin; all available P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor); or any zotarolimus, cobalt, chromium, nickel, tungsten, acrylic, or fluoropolymers; or hypersensitivity to contrast media that cannot be adequately premedicated.
  8. Have a hematologic abnormality as evidenced by hematocrit \< 25%, white blood cell \< 2,500/microliter (uL) or values \< 100,000/uL without another explanation (per investigator discretion).
  9. Have liver dysfunction, as evidenced by enzymes ( and ALT) greater than three times the .
  10. Have a bleeding diathesis or coagulopathy ( > 1.3), cannot be withdrawn from anticoagulation therapy, or will refuse blood transfusions.
  11. Be an organ transplant recipient or have a history of organ or cell transplant rejection.
  12. Have a clinical history of within the past 5 years (i.e., subjects with prior malignancy must be disease free for 5 years), except curatively-treated basal cell or squamous cell carcinoma, or cervical carcinoma.
  13. Have a condition that limits lifespan to \< 1 year.
  14. Have a history of drug or alcohol abuse within the past 24 months.
  15. Be serum positive for , surface antigen (sAg), or viremic .
  16. Be currently participating (or participated within the previous 30 days) in an therapeutic or device trial.
  17. Be pregnant, nursing, or of and not on medications. (May participate if on 2 forms of contraceptives).
  18. Any other condition that in the judgment of the Investigator would be a contraindication to enrollment or follow-up.
  19. Coronary lesions with restenosis or heavy calcification.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group

    Participants in this group will be receive a single administration of intravenous allogeneic human Mesenchymal Stem Cells (hMSCs) (100 million).

    Drug: 100 million Allogeneic Mesenchymal Human Stem Cells

  • Placebo comparator
    Group B: Placebo Group

    Participants in this group will receive a single dose of placebo (Cell-free PlasmaLyte-A medium supplemented with 1% HSA) infusion.

    Other: Placebo

Interventions

  • DrugStem CellStudies of Stem CellStem Cell pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1 single intravenous infusion

    Also known as: allo-human Mesenchymal Stem Cells (hMSCs), stem cells

  • OtherPlacebo

    Placebo delivered via peripheral intravenous infusion

06

What researchers measure

Primary outcomes

  1. Brachial Artery Flow Mediated Diameter Percentage (FMD%)

    FMD% is measured via brachial artery ultrasound. The unit of measure is percent.

    Time frame: Baseline, Week 2, Month 1, Month 3, and Month 6

  2. EPC-CFU Counts

    Endothelial progenitor cells (EPC)-colony forming units (CFUs) will be assessed from blood samples. The unit of measure is the average number of colonies per well.

    Time frame: Baseline, Week 2, Month 1, Month 3, and Month 6

Secondary outcomes

  1. Fractional Flow Reserve (FFR)

    Fractional Flow Reserve as assessed by during cardiac catheterization angiography. The values are presented as a ratio.

    Time frame: Baseline, Month 6

  2. Coronary Flow Reserve (CFR)

    Coronary Flow Reserve as assessed by during cardiac catheterization angiography. The values are presented as a ratio.

    Time frame: Baseline, Month 6

  3. Seattle Angina Questionnaire (SAQ) Angina Frequency (AF)

    SAQ is a 7 item questionnaire with a total score ranging from 0-100 with the higher scores indicating less physical limitations, less angina, symptom frequency and better quality of life. The unit of measure is score on a scale.

    Time frame: Baseline, Week 2, Month 1, Month 3, and Month 6

  4. Seattle Angina Questionnaire (SAQ) Quality of Life (QL)

    SAQ is a 7 item questionnaire with a total score ranging from 0-100 with the higher scores indicating less physical limitations, less angina, symptom frequency and better quality of life. The unit of measure is score on a scale.

    Time frame: Baseline, Week 2, Month 1, Month 3, and Month 6

  5. Number of Participants With Treatment-Emergent Serious Adverse Events (TE-SAE)

    TE-SAEs will be defined as the composite of: death, non-fatal myocardial infarction (MI), stroke, hospitalization for heart failure, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 30 sec or with hemodynamic compromise) or atrial fibrillation at 1 month post-infusion. TE-SAEs will be assessed by treating physician. The unit of measurement is the number of participants who experienced an event.

    Time frame: 1 month post infusion

  6. Number of Participants With Major Adverse Cardiac Events (MACE)

    Defined as the composite incidence of (1) death, (2) hospitalization for cardiovascular events or (3) non-fatal myocardial infarction MI at 1 year. MACE will be assessed by treating physician. The unit of measurement is the number of participants who experienced an event.

    Time frame: 12 months

  7. Number of Participants With Target Vessel Failure

    Number of participants with target vessel failure will be reported. Target vessel failure is defined as any participant that encounters revascularization, death, or MI attributed to the target vessel post-PCI (percutaneous coronary intervention). The unit of measure is number of participants.

    Time frame: 12 months

  8. Number of Participants With Treatment Emergent Adverse Events

    The number of participants who experienced a Treatment Emergent Adverse Event (AE), as assessed by study physician, will be reported. The unit of measurement is the number of participants who experienced an event.

    Time frame: 12 months

  9. Number of Participants With Abnormal Lab Values

    Number of participants with clinically significant abnormal serum hematology and clinical chemistry values will be reported. Clinical significance will be assessed by treating physician. The unit of measure is number of participants.

    Time frame: 12 months

  10. Circulating Angiogenic Marker - VEGF

    Vascular Endothelial Growth Factor (VEGF) levels from serum samples. Results are provided in units of pg/mL. Higher levels of VEGF are associated with better cardiovascular health.

    Time frame: Baseline, Month 1, Month 3, Month 6

  11. Circulating Cytokine Biomarker - TNFα

    Circulating Tumor necrosis factor alpha (TNFα) levels from serum samples. Results are provided in units of pg/mL. Lower values are associated with reduced inflammation.

    Time frame: Baseline, Month 1, Month 3, Month 6

07

Results

Posted Jun 16, 2026

Participant flow

Participant flow — Overall Study
MilestoneGroup A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo Group
Started1313
Completed1212
Not completed11
Withdrew: Lost to follow-up11

Outcome measures

PrimaryBrachial Artery Flow Mediated Diameter Percentage (FMD%)

FMD% is measured via brachial artery ultrasound. The unit of measure is percent.

Time frame:
Baseline, Week 2, Month 1, Month 3, and Month 6
Reported as:
Mean · percentage
Brachial Artery Flow Mediated Diameter Percentage (FMD%)
percentageGroup A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo Group
Baseline5.80 ± 3.464.28 ± 2.10
Week 26.98 ± 3.395.93 ± 3.13
Month 17.19 ± 2.845.64 ± 2.65
Month 37.48 ± 3.596.20 ± 2.94
Month 67.2 ± 2.935.62 ± 1.79
PrimaryEPC-CFU Counts

Endothelial progenitor cells (EPC)-colony forming units (CFUs) will be assessed from blood samples. The unit of measure is the average number of colonies per well.

Time frame:
Baseline, Week 2, Month 1, Month 3, and Month 6
Reported as:
Median · CFUs per well
EPC-CFU Counts
CFUs per wellGroup A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo Group
Baseline4.92 (1.42 to 7.38)8.67 (7.33 to 12.33)
Week 212.16 (4.46 to 17.7)11.67 (10.67 to 12.5)
Month 111.34 (4.59 to 15.75)10.75 (5.17 to 14.83)
Month 37.83 (7 to 9.16)28.5 (3.17 to 31)
Month 63.5 (0.33 to 12.7)20.83 (4.33 to 33.5)
SecondaryFractional Flow Reserve (FFR)

Fractional Flow Reserve as assessed by during cardiac catheterization angiography. The values are presented as a ratio.

Time frame:
Baseline, Month 6
Reported as:
Mean · ratio
Fractional Flow Reserve (FFR)
ratioGroup A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo Group
Baseline0.83 ± 0.240.9 ± 0.07
Month 60.9 ± 0.060.86 ± 0.08
SecondaryCoronary Flow Reserve (CFR)

Coronary Flow Reserve as assessed by during cardiac catheterization angiography. The values are presented as a ratio.

Time frame:
Baseline, Month 6
Reported as:
Mean · ratio
Coronary Flow Reserve (CFR)
ratioGroup A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo Group
Baseline2.82 ± 1.222.64 ± 1.78
Month 62.55 ± 1.93.78 ± 2.99
SecondarySeattle Angina Questionnaire (SAQ) Angina Frequency (AF)

SAQ is a 7 item questionnaire with a total score ranging from 0-100 with the higher scores indicating less physical limitations, less angina, symptom frequency and better quality of life. The unit of measure is score on a scale.

Time frame:
Baseline, Week 2, Month 1, Month 3, and Month 6
Reported as:
Mean · score on a scale
Seattle Angina Questionnaire (SAQ) Angina Frequency (AF)
score on a scaleGroup A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo Group
Baseline76.15 ± 33.5584.62 ± 25.04
Week 287.5 ± 24.5490.77 ± 11.88
Month 190 ± 17.3294.62 ± 9.67
Month 386.67 ± 25.3595.38 ± 9.67
Month 690 ± 2095.83 ± 11.65
SecondarySeattle Angina Questionnaire (SAQ) Quality of Life (QL)

SAQ is a 7 item questionnaire with a total score ranging from 0-100 with the higher scores indicating less physical limitations, less angina, symptom frequency and better quality of life. The unit of measure is score on a scale.

Time frame:
Baseline, Week 2, Month 1, Month 3, and Month 6
Reported as:
Mean · score on a scale
Seattle Angina Questionnaire (SAQ) Quality of Life (QL)
score on a scaleGroup A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo Group
Baseline53.85 ± 35.554.81 ± 24.76
Week 269.79 ± 23.5170.19 ± 29.11
Month 173.08 ± 22.7363.46 ± 25.24
Month 371.88 ± 27.7682.69 ± 26.29
Month 672.92 ± 27.6165.63 ± 32.48
SecondaryNumber of Participants With Treatment-Emergent Serious Adverse Events (TE-SAE)

TE-SAEs will be defined as the composite of: death, non-fatal myocardial infarction (MI), stroke, hospitalization for heart failure, sustained ventricular arrhythmias (characterized by ventricular arrhythmias lasting longer than 30 sec or with hemodynamic compromise) or atrial fibrillation at 1 month post-infusion. TE-SAEs will be assessed by treating physician. The unit of measurement is the number of participants who experienced an event.

Time frame:
1 month post infusion
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Serious Adverse Events (TE-SAE)
ParticipantsGroup A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo Group
Number of Participants With Treatment-Emergent Serious Adverse Events (TE-SAE)21
SecondaryNumber of Participants With Major Adverse Cardiac Events (MACE)

Defined as the composite incidence of (1) death, (2) hospitalization for cardiovascular events or (3) non-fatal myocardial infarction MI at 1 year. MACE will be assessed by treating physician. The unit of measurement is the number of participants who experienced an event.

Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Participants With Major Adverse Cardiac Events (MACE)
ParticipantsGroup A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo Group
Number of Participants With Major Adverse Cardiac Events (MACE)23
SecondaryNumber of Participants With Target Vessel Failure

Number of participants with target vessel failure will be reported. Target vessel failure is defined as any participant that encounters revascularization, death, or MI attributed to the target vessel post-PCI (percutaneous coronary intervention). The unit of measure is number of participants.

Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Participants With Target Vessel Failure
ParticipantsGroup A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo Group
Number of Participants With Target Vessel Failure02
SecondaryNumber of Participants With Treatment Emergent Adverse Events

The number of participants who experienced a Treatment Emergent Adverse Event (AE), as assessed by study physician, will be reported. The unit of measurement is the number of participants who experienced an event.

Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events
ParticipantsGroup A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo Group
Number of Participants With Treatment Emergent Adverse Events21
SecondaryNumber of Participants With Abnormal Lab Values

Number of participants with clinically significant abnormal serum hematology and clinical chemistry values will be reported. Clinical significance will be assessed by treating physician. The unit of measure is number of participants.

Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Lab Values
ParticipantsGroup A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo Group
Number of Participants With Abnormal Lab Values14
SecondaryCirculating Angiogenic Marker - VEGF

Vascular Endothelial Growth Factor (VEGF) levels from serum samples. Results are provided in units of pg/mL. Higher levels of VEGF are associated with better cardiovascular health.

Time frame:
Baseline, Month 1, Month 3, Month 6
Reported as:
Mean · pg/mL
Circulating Angiogenic Marker - VEGF
pg/mLGroup A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo Group
VEGF Baseline1,169.62 ± 379.731,303.36 ± 604.34
VEGF Month 11,220.7 ± 380.241251.62 ± 588.55
VEGF Month 31243.28 ± 432.11173.4 ± 469.88
VEGF Month 61057.23 ± 425.581234.75 ± 566.07
SecondaryCirculating Cytokine Biomarker - TNFα

Circulating Tumor necrosis factor alpha (TNFα) levels from serum samples. Results are provided in units of pg/mL. Lower values are associated with reduced inflammation.

Time frame:
Baseline, Month 1, Month 3, Month 6
Reported as:
Mean · pg/mL
Circulating Cytokine Biomarker - TNFα
pg/mLGroup A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo Group
TNFα - Baseline14.70 ± 4.4913.02 ± 2.96
TNFα - Month 114.50 ± 5.5112.90 ± 2.99
TNFα - Month 312.54 ± 2.2314.09 ± 5.08
TNFα - Month 615.53 ± 7.9018.36 ± 14.68

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group0/13 (0%)2/13 (15.4%)11/13 (84.6%)
Group B: Placebo Group0/13 (0%)4/13 (30.8%)9/13 (69.2%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventGroup A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo Group
Increased CreatinineInvestigations0/132/13
Atrial FibrillationCardiac disorders0/131/13
Acute Coronary SyndromeCardiac disorders1/130/13
Cardiac Chest PainCardiac disorders1/131/13
Heart Failure ExacerbationCardiac disorders1/130/13
Non-Cardiac Chest PainGeneral disorders1/130/13
Lung InfectionInfections and infestations0/131/13
FallInjury, poisoning and procedural complications1/130/13
Carotid Artery InjuryInjury, poisoning and procedural complications1/130/13
Pain in extremityMusculoskeletal and connective tissue disorders0/131/13
Most frequent other events
Showing 10 of 52
Most frequent other events
EventGroup A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo Group
Cardiac Chest PainCardiac disorders3/131/13
AnemiaBlood and lymphatic system disorders2/130/13
Heart Failiure ExacerbationCardiac disorders0/132/13
In stent re-stenosisCardiac disorders0/132/13
Lung InfectionInfections and infestations0/132/13
DizzinessNervous system disorders0/132/13
DyspneaRespiratory, thoracic and mediastinal disorders2/130/13
Bilateral Axillary AdenopathyBlood and lymphatic system disorders1/130/13
Atrial FlutterCardiac disorders1/130/13
PalpitationsCardiac disorders1/130/13

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo GroupTotal
Mean63.85 ± 6.4762.62 ± 10.9963.23 ± 8.95
Sex: Female, Male
Sex: Female, Male(Participants)Group A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo GroupTotal
Female123
Male121123
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo GroupTotal
Hispanic or Latino8917
Not Hispanic or Latino549
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group A: Allogeneic Mesenchymal Stem Cells (MSCs) GroupGroup B: Placebo GroupTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American022
White131124
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • University of Miami
    Miami, Florida 33136, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Mar 2025, 43 months.

Results were first posted in Jun 2026, 1 year 2 months after primary completion.

Of 40 phase 1/2 interventional studies under Diabetes Mellitus, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2021
First posted
Mar 1, 2021
StartActual
Aug 16, 2021
Primary completionActual
Mar 30, 2025
CompletionActual
Aug 26, 2025
Results first posted
Jun 16, 2026
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04776239
Lead sponsor
Joshua M Hare
Responsible party
Joshua M Hare (Professor of Clinical Medicine, University of Miami) — Sponsor-investigator
First posted
Mar 1, 2021
Start date
Aug 16, 2021
Primary completion
Mar 30, 2025
Completion
Aug 26, 2025
Results posted
Jun 16, 2026
Last update
Jun 16, 2026

Study contacts

Nikolaos Spilias, MD
principal investigator · University of Miami

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stem Cell

Start the discussion